22348-97-6Relevant academic research and scientific papers
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0247-0253, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0100-0106, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0080-0086, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0121-0124, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention uses Nap as a protecting group, and can be conveniently removed in subsequent operation. The synthesis route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0081-0086, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Intermediate, synthesis and application of vaccine adjuvant MPLA
-
Paragraph 0262-0263; 0265-0268, (2021/10/27)
The invention discloses an intermediate of a vaccine adjuvant MPLA, and synthesis and application thereof. The intermediate provided by the invention takes the allyl phosphate ligand as MPLA phosphate group source, Nap is a protecting group, and can be conveniently removed in subsequent operation. The synthesized intermediate route is short, and the total yield is obviously increased. For synthesis and amplification MPLA, a foundation is provided.
Synthesis of monophosphorylated lipid A precursors using 2-naphthylmethyl ether as a protecting group
Cai, Li,Emmanuel, Khalisha A.,Gao, Qi,Ge, Dongmian,Han, Ziyi,Li, Gen,McManus, Cynthia L.,Sui, Qiang,Xue, Jundi
supporting information, p. 1955 - 1962 (2020/10/02)
Lipid A, the hydrophobic domain of lipopolysaccharide (LPS), is a strong immunostimulator and therefore a valuable target for the development of novel immunomodulators. Various lipid A derivatives have been chemically synthesized in order to reduce toxicity while retaining the immunostimulatory activity. In this work, we describe a novel approach to the frequently problematic synthesis of monophosphorylated mono- and disaccharide lipid X using a combination of established chemistry and a novel 2-naphthyl-methyl ether (Nap) protecting group for “permanent” protection of hydroxy groups. Of particular note is the fact that the key Nap protecting group is able to remain in the molecule until the final global deprotection step. Our synthetic strategy is not only efficient in regards to the yield of the various chemical transformations, but also robust in regards to the potential application of this route to the production of other lipid A analogs.
Synthesis of monophosphoryl lipid A using 2-naphtylmethyl ethers as permanent protecting groups
Verpalen, Enrico C.J.M.,Brouwer, Arwin J.,Boons, Geert-Jan
supporting information, (2020/10/09)
Lipid A, which is a conserved component of lipopolysaccharides of gram-negative bacteria, has attracted considerable interest for the development of immuno-adjuvants. Most approaches for lipid A synthesis rely on the use of benzyl ethers as permanent protecting groups. Due to the amphiphilic character of lipid A, these compounds aggregate during the hydrogenation step to remove benzyl ethers, resulting in a sluggish reaction and by-product formation. To address this problem, we have developed a synthetic approach based on the use of 2-naphtylmethyl ether (Nap) ethers as permanent protecting group for hydroxyls. At the end of a synthetic sequence, multiple of these protecting groups can readily be removed by oxidation with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ). Di-allyl N,N-diisopropylphosphoramidite was employed to install the phosphate ester and the resulting allyl esters were cleaved using palladium tetrakistriphenylphosphine. The synthetic strategy allows late stage introduction of different fatty acids at the amines of the target compound, which is facilitated by Troc and Fmoc as orthogonal amino-protecting groups.
Ruthenium catalyzes the synthesis of γ-butenolides fused with cyclohexanones
Thombal, Raju S.,Kim, Seoung-Tae,Baik, Mu-Hyun,Lee, Yong Rok
supporting information, p. 2940 - 2943 (2019/03/26)
Ruthenium(II)-catalyzed reactions of cyclic diazodicarbonyl compounds with β-ketoamides for chemo- and stereoselective construction of cyclohexanone-fused γ-butenolides are described. This study represents the first example of the addition of an enol substrate which is formed by the tautomerization of the β-ketoamides to the electrophilic carbene center for unusual cyclization through amide cleavage. The combined experimental and computational studies shed light on the mechanistic pathway favouring the unusual ring formation reaction instead of the involvement of the general carbonyl ylide intermediates for the product generation.
An Unsaturated Quinolone N-Oxide of Pseudomonas aeruginosa Modulates Growth and Virulence of Staphylococcus aureus
Szamosvári, Dávid,B?ttcher, Thomas
supporting information, p. 7271 - 7275 (2017/06/13)
The pathogen Pseudomonas aeruginosa produces over 50 different quinolones, 16 of which belong to the class of 2-alkyl-4-quinolone N-oxides (AQNOs) with various chain lengths and degrees of saturation. We present the first synthesis of a previously proposed unsaturated compound that is confirmed to be present in culture extracts of P. aeruginosa, and its structure is shown to be trans-Δ1-2-(non-1-enyl)-4-quinolone N-oxide. This compound is the most active agent against S. aureus, including MRSA strains, by more than one order of magnitude whereas its cis isomer is inactive. At lower concentrations, the compound induces small-colony variants of S. aureus, reduces the virulence by inhibiting hemolysis, and inhibits nitrate reductase activity under anaerobic conditions. These studies suggest that this unsaturated AQNO is one of the major agents that are used by P. aeruginosa to modulate competing bacterial species.
